10 Aptamers for Thrombotic Diseases
311
References
1. Al-Horani RA, Afosah DK (2018) Recent advances in the discovery and development of
factor XI/XIa inhibitors. Med Res Rev 38(6):1974–2023
2. Keefe AD, Schaub RG (2008) Aptamers as candidate therapeutics for cardiovascular
indications. Curr Opin Pharmacol 8(2):147–152
3. Nimjee SM, Povsic TJ, Sullenger BA, Becker RC (2016) Translation and clinical development
of antithrombotic aptamers. Nucleic Acid Ther 26(3):147–155
4. Bompiani KM, Woodruff RS, Becker RC, Nimjee SM, Sullenger BA (2012) Antidote control
of aptamer therapeutics: the road to a safer class of drug agents. Curr Pharm Biotechnol
13(10):1924–1934
5. Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, Carney
RJ, Lazzam C, McKay RG, McCabe CH, Braunwald E, JUMBO-TIMI 26 Investigators
(2005) Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine
P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint
Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation
111(25):3366–3373
6. Siller-Matula JM, Krumphuber J, Jilma B (2010) Pharmacokinetic, pharmacodynamic and
clinical profile of novel antiplatelet drugs targeting vascular diseases. Br J Pharmacol
159(3):502–517
7. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ,
Ardissino D, Servi SD, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM,
TRITON-TIMI 38 Investigators (2007) Prasugrel versus clopidogrel in patients with acute
coronary syndromes. N Engl J Med 357(20):2001–2015
8. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S,
James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA,
PLATO Investigators; Freij A, Thorsén M (2009) Ticagrelor versus clopidogrel in patients
with acute coronary syndromes. N Engl J Med 361(11):1045–1057
9. Li W, Wang K, Zhao M, Yang X, Chen M, Lan X (2014) Development of aptamer oligonucleotides as anticoagulants and antithrombotics for cardiovascular diseases: current status.
Thromb Res 134(4):769–773
10. Bae ON (2012) Targeting von Willebrand factor as a novel anti-platelet therapy; application of
ARC1779, an Anti-vWF aptamer, against thrombotic risk. Arch Pharm Res 35(10):1693–1699
11. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen
DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ,
Rutsch W, Wilcox RG, Feyter PJ, Vahanian A, Topol EJ, REPLACE-2 Investigators (2003)
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned
glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2
randomized trial. JAMA 289(7):853–863
12. Kuliczkowski W, Floyd J, Malinin A, Serebruany V (2010) Aptamers: the emerging class of
future anticoagulation for vascular disease. Expert Rev Cardiovasc Ther 8(4):503–507
13. Moscucci M (2002) Frequency and costs of ischemic and bleeding complications after percutaneous coronary interventions: rationale for new antithrombotic agents. J Invasive Cardiol
14 Suppl B: 55B-64B
14. Engoren MC, Habib RH, Zacharias A, Schwann TA, Riordan CJ, Durham SJ (2002) Effect of
blood transfusion on long-term survival after cardiac operation. Ann Thorac Surg 74(4):1180–
1186
15. Nimjee SM, Rusconi CP, Harrington RA, Sullenger BA (2005) The potential of aptamers as
anticoagulants. Trends Cardiovasc Med 15(1):41–45
16. Becker RC, Rusconi C, Sullenger B (2005) Nucleic acid aptamers in therapeutic anticoagulation. Technology, development and clinical application. Thromb Haemost 93(6):
1014–1020
311
References
1. Al-Horani RA, Afosah DK (2018) Recent advances in the discovery and development of
factor XI/XIa inhibitors. Med Res Rev 38(6):1974–2023
2. Keefe AD, Schaub RG (2008) Aptamers as candidate therapeutics for cardiovascular
indications. Curr Opin Pharmacol 8(2):147–152
3. Nimjee SM, Povsic TJ, Sullenger BA, Becker RC (2016) Translation and clinical development
of antithrombotic aptamers. Nucleic Acid Ther 26(3):147–155
4. Bompiani KM, Woodruff RS, Becker RC, Nimjee SM, Sullenger BA (2012) Antidote control
of aptamer therapeutics: the road to a safer class of drug agents. Curr Pharm Biotechnol
13(10):1924–1934
5. Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, Carney
RJ, Lazzam C, McKay RG, McCabe CH, Braunwald E, JUMBO-TIMI 26 Investigators
(2005) Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine
P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint
Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation
111(25):3366–3373
6. Siller-Matula JM, Krumphuber J, Jilma B (2010) Pharmacokinetic, pharmacodynamic and
clinical profile of novel antiplatelet drugs targeting vascular diseases. Br J Pharmacol
159(3):502–517
7. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ,
Ardissino D, Servi SD, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM,
TRITON-TIMI 38 Investigators (2007) Prasugrel versus clopidogrel in patients with acute
coronary syndromes. N Engl J Med 357(20):2001–2015
8. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S,
James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA,
PLATO Investigators; Freij A, Thorsén M (2009) Ticagrelor versus clopidogrel in patients
with acute coronary syndromes. N Engl J Med 361(11):1045–1057
9. Li W, Wang K, Zhao M, Yang X, Chen M, Lan X (2014) Development of aptamer oligonucleotides as anticoagulants and antithrombotics for cardiovascular diseases: current status.
Thromb Res 134(4):769–773
10. Bae ON (2012) Targeting von Willebrand factor as a novel anti-platelet therapy; application of
ARC1779, an Anti-vWF aptamer, against thrombotic risk. Arch Pharm Res 35(10):1693–1699
11. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen
DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ,
Rutsch W, Wilcox RG, Feyter PJ, Vahanian A, Topol EJ, REPLACE-2 Investigators (2003)
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned
glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2
randomized trial. JAMA 289(7):853–863
12. Kuliczkowski W, Floyd J, Malinin A, Serebruany V (2010) Aptamers: the emerging class of
future anticoagulation for vascular disease. Expert Rev Cardiovasc Ther 8(4):503–507
13. Moscucci M (2002) Frequency and costs of ischemic and bleeding complications after percutaneous coronary interventions: rationale for new antithrombotic agents. J Invasive Cardiol
14 Suppl B: 55B-64B
14. Engoren MC, Habib RH, Zacharias A, Schwann TA, Riordan CJ, Durham SJ (2002) Effect of
blood transfusion on long-term survival after cardiac operation. Ann Thorac Surg 74(4):1180–
1186
15. Nimjee SM, Rusconi CP, Harrington RA, Sullenger BA (2005) The potential of aptamers as
anticoagulants. Trends Cardiovasc Med 15(1):41–45
16. Becker RC, Rusconi C, Sullenger B (2005) Nucleic acid aptamers in therapeutic anticoagulation. Technology, development and clinical application. Thromb Haemost 93(6):
1014–1020